JP2025118771A5 - - Google Patents

Info

Publication number
JP2025118771A5
JP2025118771A5 JP2025076718A JP2025076718A JP2025118771A5 JP 2025118771 A5 JP2025118771 A5 JP 2025118771A5 JP 2025076718 A JP2025076718 A JP 2025076718A JP 2025076718 A JP2025076718 A JP 2025076718A JP 2025118771 A5 JP2025118771 A5 JP 2025118771A5
Authority
JP
Japan
Prior art keywords
methods
new products
manufacturing methods
manufacturing
methods substantially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025076718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025118771A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/023977 external-priority patent/WO2019191026A2/en
Application filed filed Critical
Publication of JP2025118771A publication Critical patent/JP2025118771A/ja
Publication of JP2025118771A5 publication Critical patent/JP2025118771A5/ja
Pending legal-status Critical Current

Links

JP2025076718A 2018-03-27 2025-05-02 5’-アデノシン二リン酸リボース(adpr)の使用方法 Pending JP2025118771A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862648585P 2018-03-27 2018-03-27
US62/648,585 2018-03-27
US201862693021P 2018-07-02 2018-07-02
US62/693,021 2018-07-02
PCT/US2019/023977 WO2019191026A2 (en) 2018-03-27 2019-03-26 Methods for the use of 5'-adenosine diphosphate ribose (adpr)
JP2020551992A JP7242696B2 (ja) 2018-03-27 2019-03-26 5’-アデノシン二リン酸リボース(adpr)の使用方法
JP2023035224A JP7745584B2 (ja) 2018-03-27 2023-03-08 5’-アデノシン二リン酸リボース(adpr)の使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023035224A Division JP7745584B2 (ja) 2018-03-27 2023-03-08 5’-アデノシン二リン酸リボース(adpr)の使用方法

Publications (2)

Publication Number Publication Date
JP2025118771A JP2025118771A (ja) 2025-08-13
JP2025118771A5 true JP2025118771A5 (enExample) 2025-09-22

Family

ID=66647439

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020551992A Active JP7242696B2 (ja) 2018-03-27 2019-03-26 5’-アデノシン二リン酸リボース(adpr)の使用方法
JP2023035224A Active JP7745584B2 (ja) 2018-03-27 2023-03-08 5’-アデノシン二リン酸リボース(adpr)の使用方法
JP2025076718A Pending JP2025118771A (ja) 2018-03-27 2025-05-02 5’-アデノシン二リン酸リボース(adpr)の使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020551992A Active JP7242696B2 (ja) 2018-03-27 2019-03-26 5’-アデノシン二リン酸リボース(adpr)の使用方法
JP2023035224A Active JP7745584B2 (ja) 2018-03-27 2023-03-08 5’-アデノシン二リン酸リボース(adpr)の使用方法

Country Status (5)

Country Link
US (4) US10946034B2 (enExample)
EP (2) EP3773604B1 (enExample)
JP (3) JP7242696B2 (enExample)
ES (1) ES2949441T3 (enExample)
WO (1) WO2019191026A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117482102A (zh) 2016-02-18 2024-02-02 伊维萨股份有限公司 使用5′-腺苷二磷酸核糖(adpr)的方法
US10946034B2 (en) 2018-03-27 2021-03-16 Invirsa, Inc. Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
CN111714619B (zh) * 2020-07-15 2023-03-14 上海市浦东新区人民医院 成纤维生长因子6在制备缓解非酒精性脂肪性肝炎肝损伤的药物中的应用
CN112972453B (zh) * 2021-03-05 2022-04-15 中国人民解放军军事科学院军事医学研究院 MDL-800在制备抑制SARS-CoV-2病毒易感性药物中的应用
KR102789553B1 (ko) * 2021-09-07 2025-04-03 주식회사 펄스인마이어스 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
WO2025122455A1 (en) * 2023-12-04 2025-06-12 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr) for vegf modulation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273826A (ja) * 1991-02-27 1992-09-30 Dainippon Ink & Chem Inc 抗rsウイルス剤
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
JPH07247210A (ja) 1994-03-09 1995-09-26 Sunstar Inc 口腔用組成物
JP2001515916A (ja) 1997-09-11 2001-09-25 オクシジェン,インコーポレイテッド 悪性および伝染性疾患の治療用にニコチンアミド・アデニン・ジヌクレオチドならびにその類似物を用いる治療法
AR023088A1 (es) 1999-02-26 2002-09-04 Inspire Pharmaceuticals Inc Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas.
KR20020026460A (ko) 1999-06-16 2002-04-10 게리 엘. 윌콕스 인체 폴리(adp-리보스) 폴리메라제 2 물질 및 방법
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
WO2003011885A1 (en) 2001-07-25 2003-02-13 Celltech R & D Limited Non-natural carbon-linked nucleotides and dinucleotides
EP1509234B1 (en) * 2002-05-21 2008-12-17 Abbott Laboratories Treatment of mucositis
JP2005089450A (ja) 2003-08-11 2005-04-07 Fujisawa Pharmaceut Co Ltd Rsウィルスによる感染症の予防または治療剤
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20050276762A1 (en) 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
WO2006127987A2 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US9150628B2 (en) 2005-11-14 2015-10-06 Centre National De La Recherche Scientifique (Cnrs) PARP inhibitors
WO2008154129A1 (en) 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
EP2569307A2 (en) 2010-05-10 2013-03-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
CA2835343A1 (en) 2011-05-12 2012-11-15 Foresight Biotherapeutics, Inc. Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
US20160287622A1 (en) * 2013-11-18 2016-10-06 Massachusetts Institute Of Technology Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
CN117482102A (zh) 2016-02-18 2024-02-02 伊维萨股份有限公司 使用5′-腺苷二磷酸核糖(adpr)的方法
US10946034B2 (en) 2018-03-27 2021-03-16 Invirsa, Inc. Methods for the use of 5′-adenosine diphosphate ribose (ADPR)

Similar Documents

Publication Publication Date Title
JP2024156852A5 (enExample)
JP2024133471A5 (enExample)
JP2026012786A5 (enExample)
JP2024063016A5 (enExample)
JP2023113641A5 (enExample)
JP2025023938A5 (enExample)
JP2024037765A5 (enExample)
JP2023113681A5 (enExample)
JP2025106258A5 (enExample)
JP2023153863A5 (enExample)
JP2023164986A5 (enExample)
JP2024156705A5 (enExample)
JP2023134519A5 (enExample)
JP2025118771A5 (enExample)
JP2025038009A5 (enExample)
JP2024088648A5 (enExample)
JP2023103231A5 (enExample)
JP2025143267A5 (enExample)
JP2024160274A5 (enExample)
JP2023139025A5 (enExample)
JP2025124655A5 (enExample)
JP2025041678A5 (enExample)
JP2024038101A5 (enExample)
JP2023100679A5 (enExample)
JP2025163046A5 (enExample)